Intellia 'Reorganization to Prioritize Advancement of Late-Stage Programs'

 

• Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis – set foundation for significant, near-term value creation

• Phase 3 HAELO study evaluating NTLA-2002 for HAE to complete enrollment in the second half of 2025; Company plans to submit a Biologics License Application in the second half of 2026
• More than 550 patients expected to be enrolled by year end within the ongoing MAGNITUDE study for nex-z in ATTR-CM – the program remains ahead of internal enrollment estimates
• Pipeline priorities result in NTLA-3001 discontinuation and select, research-focused investment
• Anticipated cost savings, including a net workforce reduction of approximately 27% in 2025, support company operations into 1H 2027 and through anticipated, first commercial launch in the U.S.

https://www.globenewswire.com/news-release/2025/01/09/3007346/0/en/Intellia-Therapeutics-Announces-Anticipated-2025-Milestones-and-Strategic-Reorganization-to-Prioritize-the-Advancement-of-its-Late-Stage-Programs-NTLA-2002-and-Nexiguran-Ziclumeran.html